Active substance
Mivacurium
- SFDA 4
- US FDA 4
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MIVACRON 2MG\ML INJ | 2 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 41.70 | NCE · Prescription | Aspen Pharma Trading Limited | Withdrawn by MAH · Not Marketed |
| MIVACRON 2MG\ML INJ | 2 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 83.40 | NCE · Prescription | Aspen Pharma Trading Limited | Withdrawn by MAH · Not Marketed |
| MIVACRON 2MG\ML INJ | 2 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 48.55 | NCE · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| MIVACRON 2MG\ML INJ | 2 mg/ml | Solution for injection · Intravenous use | 5 Ampoule | SAR 148.40 | NCE · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MIVACRON | EQ 2MG BASE/ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 10MG BASE/5ML (EQ 2MG BASE/ML); EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | solution · intravenous | ABBVIE | Discontinued | 22 Jan 1992 |
| MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER | EQ 0.5MG BASE/ML; EQ 50MG BASE/100ML | injectable · injection | ABBVIE | Discontinued | 22 Jan 1992 |
| MIVACURIUM CHLORIDE | EQ 2MG BASE/ML | injectable · injection | RISING | Discontinued | 30 Apr 2009 |
| MIVACURIUM CHLORIDE | EQ 10MG BASE/5ML (EQ 2MG BASE/ML); EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | solution · intravenous | WOODWARD | Discontinued | 12 Oct 2021 |
Safety signals and safety-related labeling changes
- US FDA 26 Jul 2018 MIVACRON — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.